glp 1 prescription weight loss medications What to Make of the GLP-1 Coverage and Cost Landscape GLP-1

The evidence base is primarily observational and retrospective , with limited randomised controlled trial data specifically in post-bariatric populations

K.McbrideS

Extensive clinical experience has been reported using these medications in a wide spectrum of patients with T2DM and concomitant cardiovascular disease, chronic kidney disease, or obesity, among others

Whilst GLP-1 agonists were initially developed for type 2 diabetes management, their weight loss effects have become increasingly recognised

addition of RBV and/or extended therapy duration modestly increased SVR12 rates in these populations.[11] Current treatment guidelines recommend SOF + DCV with or without RBV for 24 weeks in patients with GT3 infection and compensated cirrhosis.[12, 13] The DAA combination of SOF and velpatasvir (VEL) for 12 weeks resulted in SVR12 rates between 89% and 91% for HCV GT3-infected patients with compensated cirrhosis and/or prior treatment experience.[14] The American Association for the Study of Liver Diseases recommends viral resistance testing prior to treatment with SOF/VEL in treatment-naive patients with compensated cirrhosis or in prior pegylated interferon (pegIFN)/RBV treatment-experienced patients without cirrhosis